Life Biosciences has released the first human data for ER-100, a therapy built on partial epigenetic reprogramming. The Boston company reported that one injection into the eye, combined with daily oral doxycycline, was well tolerated through Day 56 in all three participants with open-angle glaucoma. It also reported early signs of visual-field improvement in two of the three1. An independent data safety monitoring board recommended that the trial move to a higher dose1.
What Life Biosciences reported
Chief scientific officer Sharon Rosenzweig-Lipson presented the interim results on October 8, 2026, in an oral session at Eyecelerator @ American Academy of Ophthalmology 2026 in New Orleans2. She described the data as coming from “the first 3 participants in our glaucoma cohort at the lowest dose of ER-100”3.
The company listed these findings1:
- Each participant received one intravitreal injection (an injection into the gel inside the eye) of Dose Level 1, 2×10¹¹ vector genomes, plus daily oral doxycycline to switch on the therapy’s genes.
- No dose-limiting toxicities, adverse events of special interest or serious adverse events were reported.
- The company said all reported adverse events were related to the procedure, the steroid or pre-existing conditions, and were not directly associated with ER-100.
- At Day 56, two of three participants showed improvements on Humphrey visual field testing, a standard exam that scores how well a person detects light at many points across their vision, in decibels (dB).
- In each of those two participants, at least 28% of tested points improved by more than 4 dB.
The data safety monitoring board recommended moving to Dose Level 2, 6×10¹¹ vector genomes, in glaucoma participants1. Business Insider described this as a threefold dose increase for the next group of patients4.
While this Phase 1 study is designed to evaluate safety and tolerability, the preliminary observations of visual field improvements in two participants are encouraging as we continue to advance the ER-100 program.
Rosenzweig-Lipson made that statement in the company’s announcement1.
How the treatment works
ER-100 targets retinal ganglion cells, the neurons that connect the eye to the brain. The company notes that these cells do not naturally regenerate, so damage to them causes permanent vision loss1. In open-angle glaucoma, the disease often keeps progressing despite treatment, and some patients have it even when their eye pressure is normal1.
The therapy uses a viral vector (AAV-2) to deliver three transcription factors, OCT4, SOX2 and KLF4, known together as OSK. Their expression is switched on by doxycycline taken for 8 weeks1. Participants also take a tapering course of oral prednisolone to lower the risk of inflammation from an immune response to the AAV-2 vector1.
These are three of the four genes Shinya Yamanaka used in Nobel Prize-winning work in 2012 to turn adult cells back into an embryonic-like state5. Full reprogramming with all four factors carries a risk of teratomas, a type of tumor. The approach behind ER-100 drops the factor most associated with cancers and tries to return cells only to a point before they stopped working properly5.
Before the human trial, the company reported that in a nonhuman primate model of NAION (non-arteritic anterior ischemic optic neuropathy, a sudden loss of vision caused by poor blood flow), ER-100 restored DNA methylation patterns. Earlier work in the same model had shown restored cell function on pattern electroretinogram, a test of retinal electrical activity6. These were animal results, presented by the company.
What the data do not show yet
The trial is first-in-human, Phase 1 and open-label, which means everyone receives the therapy and knows it. Its main purpose is to assess safety and tolerability1. The data come from three people followed for 56 days. They are interim results from an ongoing trial1, presented at a meeting and in a press release rather than in a peer-reviewed paper. The company’s release does not describe the third participant’s visual-field result beyond reporting improvements in two of three1.
Without a control group, the visual-field changes cannot be separated from test-to-test variation, learning effects or other factors. James Tsai, president of New York Eye and Ear Infirmary of Mount Sinai and a glaucoma specialist not involved in the trial, called the news “exciting” but very preliminary4. He said the therapy may not have regenerated the eye and could instead have improved existing electrical signals in patients who still had some vision4.
I need a lot more information to say, ‘Hey, we’re truly at the holy grail of really reversing vision [loss],’
Tsai told Business Insider. He added: “The exciting thing is they’ve done it in humans.”4
The trial also plans to include people with NAION7, but the reported data cover only the glaucoma cohort3.
Who is behind it
The therapy is based on work from the lab of David Sinclair, professor of genetics at Harvard Medical School and co-founder of Life Biosciences5. TIME reported that Sinclair and his graduate student Yuancheng Lu began studying the three-factor approach in mice with age-related vision loss5. Sinclair argues that aging cells lose function because of accumulated epigenetic “noise,” the confused instructions that tell genes when to switch on or off5.
When the first participant was dosed, Sinclair said the study was the first chance to test whether restoring epigenetic information can affect human disease8.
Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage.
Sinclair said this in the company’s statement, as reported by The Ophthalmologist8. All of the efficacy and safety claims so far come from the company and its executives, who have a financial interest in the program. Healio’s disclosure notes that Rosenzweig-Lipson is Life Biosciences’ chief scientific officer7. The sources reviewed for this article do not say who funds the trial or the company.
How it fits the field
The FDA cleared Life Biosciences’ investigational new drug application in January 2026. The company said ER-100 was the first therapy of its kind cleared to start human trials7. The Ophthalmologist reported in July 2026 that the first participant had been dosed8. The company’s own description says the Phase 1 trial was initiated in the first quarter of 20261.
Business Insider describes ER-100 as the first human trial of cellular reprogramming. The technique has previously been tested in mice and monkeys4. Other companies are working toward the clinic. Altos Labs hired clinical trial expert Joan Mannick as head of product development. New Limit raised $435 million in a Series C round and has said it aims to start human trials of a liver-cell reprogramming therapy in 2027. Retro Biosciences is also researching the approach4.
Life Biosciences chief operating officer Michael Ringel pointed to animal studies in other age-related conditions. He said the approach “will have to be shown clinically. We have to prove it, not just think it.”4 The company has also reported preclinical results for a separate program, ER-300, in a mouse model of the liver disease MASH6.
What to watch next
- Dose Level 2. Safety and visual-field data from glaucoma participants at the higher dose1.
- NAION cohort. First data in people with NAION, a condition with no approved treatments1.
- Durability. Whether any changes persist after doxycycline stops at Day 56. The current data do not go beyond that point1.
- Published data. A peer-reviewed report with full per-participant results. The company has said the Phase 1 data will guide dose selection and the design of later studies7.
